Research programme: protein therapeutics - Lee's PharmaceuticalAlternative Names: ZK002
Latest Information Update: 14 Oct 2015
At a glance
- Originator Lees Pharmaceutical Holdings
- Class Proteins
- Mechanism of Action Angiogenesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Eye disorders
- Discontinued Cancer
Most Recent Events
- 21 Mar 2012 Preclinical trials in Cancer in Hong Kong (unspecified route)